CoChat

The anti-depressant effects of a novel PDE4 inhibitor derived from resveratrol

Open access
Yu, Yingcong, Wang, Jinhui, Huang, Xianfeng · 2021 · Pharmaceutical Biology

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Context Resveratrol has shown anti-stress and anti-depressant-like abilities involved in inhibiting phosphodiesterase-4 (PDE4) enzyme. However, its application is limited due to its low efficacy, bioavailability and selectivity.Objective This study synthesized a new resveratrol derivative RES003 and evaluated its PDE4 inhibitory and anti-depressant-like activities in vitro and in vivo, respectively.Materials and methods PDEs inhibitory activities were evaluated by radioactive tracer method. Anti-depressant-like activities of novel resveratrol analogue (RES003) at doses of 2.5, 5.0 and 10 mg/kg was investigated by sugar water consumption and forced swimming tests using male ICR mice under chronic unpredictable stress procedure for 10 days. A total of 84 mice were randomly distributed into seven groups (n = 12). Drugs and vehicle were administered (intra-gastric or intra-peritoneal) once a day from the first to the last day. The molecular mechanisms were identified by western blot.Results RES003 showed more potent PDE4 inhibitory activity (half maximal inhibitory concentration (IC50), 0.87 μM) and better selectivity than resveratrol (IC50, 18.8 μM). RES003 could significantly increase the consumption of sugar water (p < 0.01) and immobility time (p < 0.01) compared to vehicle-treated stressed groups at doses of 5 and 10 mg/kg. Furthermore, RES003 could significantly increase the levels of cyclic adenosine monophosphate response element binding protein phosphorylation (10 mg/kg, p < 0.05) and brain-derived neurotrophic factor (BDNF) expression (5 and 10 mg/kg, p < 0.05 and 0.01) in mouse brain.Discussion and conclusions RES003 could ameliorate chronic stress induced depression-like behaviours through inhibition of PDE4 and activation of cAMP-triggered phosphorylation of cAMP response element binding protein/BDNF signalling pathway. Consequently, RES003 is a promising lead compound for the treatment of depression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/13880209.2021.1907422

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. The structures of resveratrol and RES003.
Figure 1. The structures of resveratrol and RES003.CC BY · PubMed Central
Scheme 1. Synthesis of RES003. Reagents and conditions: (a) PPTs, CH2Cl2, room temperature; (b) NaOH, CH3OH, reflux; (c) PPTs, C2H5OH, 50 °Cand (d) hydrazine hydrate, CH3COOH, C2H5OH, reflux.
Scheme 1. Synthesis of RES003. Reagents and conditions: (a) PPTs, CH2Cl2, room temperature; (b) NaOH, CH3OH, reflux; (c) PPTs, C2H5OH, 50 °Cand (d) hydrazine hydrate, CH3COOH, C2H5OH, reflux.CC BY · PubMed Central
Figure 2. Binding mode of compound resveratrol and RES003 within the active pocket of PDE4 (PDB ID: 1UDU). Hydrogen bonds are represented by dashed lines.
Figure 2. Binding mode of compound resveratrol and RES003 within the active pocket of PDE4 (PDB ID: 1UDU). Hydrogen bonds are represented by dashed lines.CC BY · PubMed Central
Figure 3. The anti-depressant-like effects of RES003 in mice. Mice were treated with vehicle, RES003, and fluoxetine 30 min before being subjected to the (A) SPT and (B) FST. (C) Mice were treated with various doses of RES003 30 min before the locomotor activity test. Results are expressed as mean ± SEM (n = 9–10). ##p < 0.05 and ###p < 0.001 versus vehicle-treated control group. *p < 0.05 and **p < 0.01 versus model group. K: control; M : CUS model; Flu: fluoxetine.
Figure 3. The anti-depressant-like effects of RES003 in mice. Mice were treated with vehicle, RES003, and fluoxetine 30 min before being subjected to the (A) SPT and (B) FST. (C) Mice were treated with various doses of RES003 30 min before the locomotor activity test. Results are expressed as mean ± SEM (n = 9–10). ##p < 0.05 and ###p < 0.001 versus vehicle-treated control group. *p < 0.05 and **p < 0.01 versus model group. K: control; M : CUS model; Flu: fluoxetine.CC BY · PubMed Central
Figure 4. Effects of RES003 on CUS-induced decreases in the ratio of pCREB/CREB and BDNF expression in the brain tissue. Results are expressed as mean ± SEM (n = 9–10). ##p < 0.05 versus vehicle-treated control group. *p < 0.05 versus model group. Rol: rolipram.
Figure 4. Effects of RES003 on CUS-induced decreases in the ratio of pCREB/CREB and BDNF expression in the brain tissue. Results are expressed as mean ± SEM (n = 9–10). ##p < 0.05 versus vehicle-treated control group. *p < 0.05 versus model group. Rol: rolipram.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 14

Metadata

Authors
Yu, Y., Wang, J., & Huang, X.
Affiliations
  • Wenzhou Medical University (CN)
  • Changzhou University (CN)
Corresponding author
Huang, Xianfeng
Venue
Pharmaceutical Biology
Published
2021-01
Volume
59
Issue
1
Pages
416-421
ISSN
  • 0925-1618 (ISSN-L)
  • 1388-0209
  • 1744-5116
OpenAlex
W3153195639
Cited by
14
References
28
Citations by year
2026: 4 · 2025: 1 · 2024: 4 · 2023: 4 · 2021: 1
FWCI
0.71
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutical Biology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation (81970475)
  • Basic Public Research Program of Zhejiang Province (LBY21H030002)
  • Natural Science Foundation of Zhejiang Province (LY18H030005)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
resveratrol derivatives, phosphodiesterase-4 inhibitors, antidepressant effects, chronic unpredictable mild stress, depression-like behavior, brain-derived neurotrophic factor, cAMP signaling, forced swim test
MeSH terms
Resveratrol, Cyclic AMP, Animals, Antidepressive Agents, Depression, Disease Models, Animal, Dose-Response Relationship, Drug, Male, Mice, Inbred ICR, Stress, Psychological, Signal Transduction, Inhibitory Concentration 50, Mice, Phosphodiesterase 4 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The anti-depressant effects of a novel PDE4 inhibitor derived from resveratrol. https://app.cochat.ai/papers/10.1080/13880209.2021.1907422
The paper
Yu, Y., Wang, J., & Huang, X. (2021). The anti-depressant effects of a novel PDE4 inhibitor derived from resveratrol. Pharmaceutical Biology. https://doi.org/10.1080/13880209.2021.1907422

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.